Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONALEESA-3
2015-000617-43Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Ribociclib + fulvestrant with Placebo + fulvestrant (2 arms). Primary endpoint: Progression-free survival. Started Apr 2015; status: completed.
02
Drugs
ribociclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-000617-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000617-43.